IRVINE, Calif., Dec. 12, 2014 (GLOBE NEWSWIRE) -- Praxsyn Corporation (OTCQB:PXYN), today announced that its wholly owned subsidiary, Mesa Pharmacy Inc., a medication and service provider for medical practitioners, has continued to make progress towards its goal of dispensing its customized medications nationwide. "We believe in our products and we are excited to help patients nationwide," said Andrew Do, Chief Pharmacist, Mesa Pharmacy. The company is now licensed to dispense its medications in the following 22 states:
- Arizona – Y005936
- California – PHY50766
- Colorado – OSP.0006527
- Connecticut – PCN.0002821
- Florida – PH27082
- Hawaii – PMP705
- Illinois – 54.018647
- Indiana – 64001705A
- Iowa – 4429
- Kansas – 22-44650
- Missouri – 2014038089
- Nevada – PH03201
- New Jersey – 28RO00109500
- New Mexico – PH00003756
- New York – 33063
- Oklahoma – 99-6802
- Rhode Island – CPHN10740
- South Dakota – 400-1369
- Texas – 29457
- Washington – PHNR.FO.60488183
- Wisconsin – 1221-43
- Wyoming – NR-50910
About Praxsyn Corporation
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients. Additional company information can be found at www.praxsyn.com.
Forward-Looking Statements
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) including but not limited to the statement regarding the anticipated results of these added licenses to dispense medicines, and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.